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Objective: The aim of this study was to determine relative contributions of transplacental flux vs.
fetal production for inositol and mannose in normal term pregnancies.
Study Design: Seven term uncomplicated pregnancies undergoing cesarean section were infused
with 13C- and 2H-labeled isotopes of glucose, inositol, and mannose until a steady state was
achieved. Maternal and fetal concentrations of labeled and unlabeled glucose, mannose, and
inositol were measured using gas chromatography/mass spectroscopy. The fetomaternal molar
percentage excess ratio was calculated for each glucose, mannose, and inositol.
Results: The fetomaternal molar percentage excess ratio of mannose in the fetal artery (Fartery/M)
was 0.99 [97.5% confidence interval (CI), 0.91–1.07] and in the fetal vein (Fvein/M), 1.02 (97.5% CI,
0.95–1.10). Both were not significantly different from 1.0, consistent with transplacental supply.
The fetomaternal ratios forglucosewere similar tomannose (fetalartery, 0.95;97.5%CI, 0.84–1.15;
and fetal vein, 0.96; 97.5% CI, 0.85–1.07). The fetomaternal ratio for inositol was significantly less
than 1.0 (fetal artery, 0.08; 97.5% CI, 0.05–0.12; fetal vein, 0.12; 97.5% CI, 0.06–0.18), indicating
little transplacental flux and significant fetal production.
Conclusion: In normal termpregnancies, fetalmannoseandglucose concentrations aredependent
upon maternal transplacental supply. Fetal inositol is not dependent upon transplacental supply.
(J Clin Endocrinol Metab 97: 2497–2502, 2012)
Considerable information is available about the trans-port of glucose in human pregnancies (1–4); little
data are available for other polyols and “trace” or nong-
lucose carbohydrates that are present inmaternal and fetal
blood. The lack of data may be due to the untested as-
sumption that other carbohydrates and polyols are pro-
duced fromglucose, and fetal requirementsmaybemet via
production frommaternally derived glucose (5). Based on
this assumption, maternal supply of carbohydrates and
polyols other than glucose would be unnecessary. Inositol
can be formed through the polyol pathway (6). Mannose
is biologically active as D-mannose, and inositol is biolog-
ically active as myo-inositol. Both have important roles in
fetal and neonatal development.
Inositol is associated with a variety of human diseases.
Some of the diseases associated with abnormal inositol
metabolism are Lowe syndrome, myotublar myopathy,
Charcot-Marie-Tooth type 4B1disease, Francois-Neetens
fleck cornea dystrophy, and Joubert syndrome (7). Previ-
ous studies have shown relatively high concentrations of
inositol from the earliest stages of human development
throughout fetal life (8). Inositol and sorbitol are among
the five organic osmolytes used to regulate transcellular
osmotic gradients (9).Although this iswell studied in renal
epithelial cells, there is little information about their roles
in early development within the placenta. Recently,
NFAT5 (nuclear factor of activatedT cells 5), a regulatory
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protein, has been identified as playing a role in osmolyte
synthesis for inositol in the human placenta (10). Inositol
has been linked to a variety of functions including its role
in insulin signal transduction, intracellular calcium con-
centration control, and cell membrane potential (11). Ino-
sitol is also important in the formation of the neural sys-
tem, and maternal inositol deficiency has been
associated with the development of spina bifida in their
offspring (12–14). Inositol plays a role in the regulation
of surfactant phospholipid production (15, 16). It is
unknown whether or not transplacental alterations of
inositol could lead to abnormal function postnatally.
Recent studies on human fibroblasts have shown that
the synthesis ofmannose glycans requires an external sup-
ply of mannose, although theoretically it could be pro-
duced from glucose (17). Thus, the roles of inositol and
mannose are important to define in human development.
A recent study (18) has shown that embryonic lethality in
mice with a hypomorphic phosphomannomutase 2 gene
defect can be prevented by feeding the pregnantmiceman-
nose, which indicates both the importance of mannose
glycosylation during embryonic development and the
availability of maternal plasma mannose to the fetuses.
In a previous study by Battaglia et al. (19), inositol levels
in maternal and fetal blood for ovine pregnancies were re-
ported. However, at that time, it was difficult to determine
theconcentrationsofsugarsandpolyolspresent inovinefetal
blood at low concentrations due to technical limitations. As
technology improved, the fetal concentrations of mannose
and inositol were determined first in ovine pregnancies (20).
Inasubsequentclinical studybyBrusatietal. (21), fetal levels
of mannose were tightly correlated with maternal concen-
trations, which suggests dependence upon uptake from the
maternalcirculation. Inthesamestudy, inositolhadhigherfetal
compared with maternal concentrations, and it was hypothe-
sized that inositol is produced by the fetus without significant
fetal transfer from the maternal circulation. Only by labeling
glucose, mannose, and inositol can one definitively determine
whether the fetal mannose and inositol concentrations are a
result of maternal supply or derive from fetal or placental pro-
duction from glucose at the fetal or placental level.
Our hypothesis was that the fetal isotopic enrichment of
mannosewould be approximately equal to thematernal iso-
topic enrichment, just as it is for glucose. Thus, without any
appreciable dilution of fetal mannose, there would be no
evidence of significant fetal production of mannose. For
mannose, thiswould be further confirmed by the infusion of
labeled glucosem2 into the maternal circulation, verifying
lack of fetal conversion of 13C glucosem2 to
13C man-
nosem2. These findings would establish unequivocally that
fetal requirements for mannose are met primarily by trans-
placental transport, and not via fetal production from
glucose.
Our second hypothesis is that the fetal isotopic enrich-
ment of 2H inositolm6 is significantly less than the ma-
ternal isotopic enrichment, demonstrating minimal trans-
placental flux of inositol. This would establish that fetal
inositol requirements are met by fetal production from
glucose rather than by transplacental transport.
Subjects and Methods
Subjects
This study was approved by the Institutional Review Boards
at the two universities participating in the study. The study was
supported by the National Institutes of Health, the University
Pediatric Clinical Translational Research Center, the Associa-
tion for Study ofMalformations, and theMarch of Dimes.Writ-
ten informed consent was obtained from each mother by one of
the study investigators. Pregnant patients who were scheduled
for delivery by elective cesarean section for clinical indications at
term were recruited from the obstetrical services at the two par-
ticipating universities. Patients undergoing elective cesarean sec-
tion were chosen to eliminate the variable of active labor and
labor induction agents on placental transport. The two centers
collaborated on other similar projects previously.
Normalpregnanciesweredefinedas thosewithmotherswith-
out chronic diseases or diseases developed during pregnancy and
with ultrasound studies showing normal fetal growth rate and
absence of congenital anomalies. Minorities were included as
represented in the populations served at the two sites. The ob-
stetric service at one of the university hospitals includes approx-
imately a 30% Hispanic population and a 12% Black popula-
tion.At theotheruniversity hospital, theminority representation
is 70% Italian and 30% Black/Asian population. Exclusion cri-
teria included the presence of maternal infection, chromosomal
abnormalities or congenital anomalies, multiple pregnancies
(twins or higher order multiple gestations), emergency cesarean
sections, and mothers with chronic disease.
Study protocol
Two hours before the time of elective cesarean delivery, two
maternal “arterialized” venous control samples were taken as
previously described (22). The amount of infusates used is based
on the maternal weight. The goal is to achieve an isotopic en-
richment of between 2 and 10%. The lower limit is necessary to
allow an accurate measurement of the isotopic enrichment. An
upper limit is necessary to minimize altering the physiological
concentrations of the compounds of interest. Each infusate un-
derwent pyrogen and sterility testing by a research pharmacist
before use. After the control samples were taken, a maternal
infusion of the three carbohydrates was given. For D-[1,2-13C]g-
lucose (glucosem2), the infusion rate was 0.1 mg/kg  min, with
a priming dose of 5.7 mg/kg as used in previous studies (20). For
D-[1-13C]mannose, (mannosem1), the infusion rate was 0.004
mg/kg  min, with a priming dose of 0.12 mg/kg. The infusion
rate for [2H6]inositol (inositol m6) was 0.004 mg/kg  min, and
the priming dose was 0.05 mg/kg. The infusion of mannosem1
and inositolm6 into the maternal circulation over 2 h was used
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to establish the degree of transplacental flux of these two car-
bohydrates and to determine whether there is evidence of fetal
and/or placental production of either of these substrates. Before
delivery, a minimum of two samples were taken 30 min apart to
determinewhether (verify that) a steady statewas accomplished.
At the time of delivery, a thirdmaternal arterialized venous sam-
ple was taken along with arterial and venous umbilical cord
blood samples. The glucosem2 infusion was given to determine
the conversion of glucose to mannosem2.
Carbohydrate analysis
Allose and chiro-inositol, which are stereoisomers of man-
nose and inositol, respectively,were used as internal standards to
account for the loss of carbohydrate during the following sample
preparation and derivatization steps. The internal standards
have different retention times from the compounds of interest on
the gas chromatographic system. Thus, the order of elution is
allose,mannose, glucose, chiro-inositol, andmyo-inositol.There
is baseline separation of all these compounds using this chro-
matographic system. Human plasma glucose concentration is
approximately 40-fold higher than mannose concentration.
Chromatographically, the high glucose concentration interferes
with the determination of mannose concentration. Therefore,
for the determination of mannose enrichment, glucose was re-
moved from each sample by the action of glucose oxidase (23).
Plasma (0.05 ml) was added to 0.2 ml water and 0.05 ml of
internal standards (10 mg/liter of chiro-inositol and 10 mg/liter
of allose), followed by 280 U of catalase and 12 U of glucose
oxidase. After incubating at ambient temperatures for 90 min,
the reaction was stopped by the addition of 0.15 ml of 0.3 mol/
liter ZnSO4 and 0.15 ml of 0.3 mol/liter Ba(OH)2. The protein
precipitate was removed by centrifugation at 13,000  g for 4
min at 4 C. The supernatant was transferred to a test tube and
dried under a vacuum. For glucose enrichment, only 0.01 ml
plasma was used, and the glucose oxidase treatment was
omitted.
Isotopic enrichments were determined using gas chromatog-
raphy/mass spectroscopy (model 5975; Agilent Technologies,
Santa Clara, CA) equipped with an HP5-MS column (30 m 
0.25mm0.25m).Heliumwasusedas the carrier gasat a flow
rate of 1ml/min.The injector inlet and the transfer linewere both
maintained at 280 C. The initial column temperature was 120 C
and held for 1min. The column temperaturewas then ramped at
a rate of 12 C/min to 179 C and held for 8 min. Finally, column
temperature was ramped at a rate of 50 C/min to 320C and held
for 1 min to clean the column. Mannose was converted to the
aldononitrile peracetate, and inositol was converted to the per-
acetate (21). A total of 0.1 ml hydroxylamine hydrochloride (20
g/liter in anhydrouspyridine)was added to thedried residue.The
pyridine solution was incubated at 90 C for 30 min. After cool-
ing, 0.075 ml of acetic anhydride was added, and the solution
was incubated for another 30min at 90 C. After cooling, 1 ml of
1 mol/liter HCl was added, followed by 2 ml chloroform. The
mixturewas vortexed, and after the separation of the phases, the
aqueous layer was removed and discarded. The chloroform so-
lution was washed with another 1 ml of 1 mol/liter HCl, then
washed sequentially three times using 1 ml of water and then
dried. The residue was dissolved in 0.05 ml acetonitrile. Man-
nosewasmonitoredat amass/charge ratioof 314, 315, 316, 319,
320, and 321. Inositol was monitored at a mass/charge ratio of
373, 374, 375, 379, 380, and 381. For mannose, the ratio of the
315:314 peaks was used to monitor the m1 molar percentage
excess (MPE), and the ratio of the 316:314 peaks was used to
monitor the m2 MPE. For inositol, the ratio of the 375:373
peaks was used to monitor the m2 MPE, and the ratio of the
379:373 peaks was used to monitor the m6MPE. The plasma
concentrationsofmannoseand inositolwere calculatedusing the
total ion counts of the corresponding ions. The total ion counts
were compared with standard curves constructed using unla-
beled mannose and inositol.
Calculations and statistics
Maternal and fetal characteristics are calculated as means,
ranges, number and percentage. The mean maternal MPE
(Mmpe) is calculated as themeanof theMmpemeasurements once
a steady state was achieved. The mannose and inositol ratios of
fetal MPE (Fmpe)/Mmpe are calculated with 97.5% confidence
intervals (CI) to demonstrate equivalence to, or difference from,
1. A secondary analysis tests that the slope in a linear regression
of Fmpe as a function of Mmpe is equal to 1.
Results
From both university hospital study sites, a total of seven
study subjects completed the studyprotocol.A total of five
mother-fetus pairs were enrolled at one university hospi-
tal, and two patients were enrolled at the other university
hospital. There were no patients enrolled who did not
complete the study, and there were no observed compli-
cations from the infusate. Characteristics of the studied
population are presented in Table 1. All newborns were
appropriate for gestational age for birth weight; oxygen-
ation and acid-base balance were within the normal range
for all of the studied fetuses according to data published
previously (23).
Carbohydrate enrichments
Thematernal plasmaMPE after bolus infusion for glu-
cose, mannose, and inositol is depicted in Fig. 1, A–C.
TABLE 1. Maternal, fetal, and newborn infant clinical
data
Variable





Multiparity (no. of patients) 3







Birthweight (g) 3369 (3180–3632)
Data are expressed as mean (range) or number (percentage).
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Serial maternal samples were taken before delivery to en-
sure that the infusate was at a relative steady state before
delivery.
The fetal arterial and venous plasma enrichments for
glucose (m2), mannose (m1), and inositol (m6) are
presented in Table 2. There were no significant amounts
of m1 or m6 detected for glucose, with the primary
form being m2. For mannose, there were no significant
amounts ofm2 orm6 detected, with the primary form
being m1. For inositol, there were no significant
amounts ofm1 orm2 detected, with the primary form
being m6. (The significance of this is that m2 enrich-
ment for mannose and inositol was negligible.)
Fetal-to-maternal enrichment ratios
Figure2presents the fetal tomaternal (F/M)MPEratios
for both the umbilical vein and umbilical artery for glu-
cose, mannose, and inositol. The Fartery/M MPE and the
Fvein /M MPE for mannose was 0.99 (97.5% CI, 0.91–
1.07) and 1.02 (97.5% CI, 0.95–1.10), respectively. We
consider these estimates to be equivalent to 1 because the
97.5% CI do not include estimates that would be consid-
ered clinically different from1. The Fartery/MMPEand the
Fvein/MMPE for inositol was 0.08 (97.5%CI, 0.05–0.12)
and 0.12 (97.5% CI, 0.06–0.18), respectively. For man-
nose and glucose, the slope estimates from linear regres-
sions of the Fmpe as a function of the Mmpe were not sig-
nificantly different from 1, with estimates of 0.91 (97.5%
CI, 0.56–1.27) and 1.08 (97.5% CI, 0.43–1.73), respec-
tively. For inositol, the slope estimate is significantly dif-
ferent from 1, with an estimate of 0.08 (97.5%CI,0.12
to 0.28; P  0.0001).
Discussion
There have been several studies describing transplacental
gradients of glucose in both animal and human subjects
(1–4, 20, 21). Our study presents the first data describing
the normal steady-state fetal-to-maternal plasma enrich-
ments for mannose and inositol using stable isotopes. Pre-
vious studies have described the maternal and fetal con-
centrations ofmannose and inositol in pregnant sheep and
also in humans. These studies established that there were
significant umbilical veno-arterial concentration differ-
ences for glucose and mannose in human and ovine preg-
nancies. However, there was nomeasurable umbilical up-
take of inositol in human pregnancies. Because stable
isotopes were not used, these studies could not determine
FIG. 1. Maternal plasma MPE for glucose (A), mannose (B), and
inositol (C) after bolus of infusate, with time 0 being delivery and with
30, 60, 90, and 120 indicating minutes before delivery. There
are seven lines, with each line/symbol representing a maternal subject
and each symbol indicating a maternal sample.
TABLE 2. Plasma enrichments for glucose (m2), mannose (m1), and inositol (m6)
Patient no.
Glucose (m2) Mannose (m1) Inositol (m6)
Arterial Venous Arterial Venous Arterial Venous
1 3.26 3.30 6.43 6.46 1.32 1.31
2 2.89 2.82 5.94 5.91 1.53 2.22
3 2.11 1.96 7.76 8.28 1.05 1.67
4 2.60 2.95 5.47 5.88 1.31 1.92
5 3.30 3.40 6.80 7.39 1.83 2.48
6 1.16 1.18 3.74 3.65 0.46 0.41
7 2.10 2.08 4.32 4.57 0.75 1.58
Mean (SD) 2.49 (0.76) 2.53 (0.81) 5.78 (1.40) 6.02 (1.58) 1.18 (0.47) 1.66 (0.68)
Data are expressed as fetal arterial and venous MPE.
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the origin of fetal inositol and fetal mannose. The present
study extends those observations by examining the fetal/
maternal plasma enrichment ratios for the three carbohy-
drates after a steady-state infusion into the maternal cir-
culation. In both the Teng et al. (20) and Brusati et al. (21)
studies, there was a higher level of inositol present in the
fetus than in the maternal circulation, indicating either
active transport against a concentration gradient or fetal-
placental production of inositol.
The F/MMPE ratios of 0.99 for mannose and 0.08 for
inositol support our hypothesis. More specifically, the
F/M MPE ratio of 0.99 clearly demonstrates that over
95% of fetal plasma mannose originates from transpla-
cental maternal supply and follows its concentration gra-
dient frommother to fetus, similar to that of glucose. The
F/M MPE ratio for glucose was 0.93, which is similar to
prior studies (1–4) and, once again, confirms that in nor-
mal human pregnancies, there is little if any fetal gluco-
neogenesis taking place. In contrast, the higher fetal con-
centration of inositol does not appear to be maternally
derived with an F/MMPE ratio of 0.09, which establishes
that less than 10% of fetal plasma inositol is derived from
maternal plasma. This observation in term pregnancies is
especially interesting in light of a prior study (8) showing
that inositol levels are elevated during the first trimester.
Our study in term pregnancies shows that little of the fetal
plasma inositol is maternally derived, but it raises ques-
tions of why inositol levels in the first trimester are ele-
vated and whether the fetal inositol is of maternal origin.
One theory for this apparent discrepancy is that the fetus
may be more dependent on maternal inositol transfer in
the first trimester of pregnancy than at full term.
Labeled glucose was used to confirm that the study
designwould yield glucose results comparable to previous
studies and, secondarily, to determine whether the fetal
mannose was produced from mater-
nally derived glucose. In our study,
there was no detectable conversion of
13C glucosem2 to
13C inositolm2 or
13C mannosem2. For mannose, these
results are significant and support the
conclusion that fetal plasmamannose is
derived from maternal plasma man-
nose by transplacental passage. How-
ever, the absence of glucose labeling of
inositol carries little biological signifi-
cance because inositol concentrations
in placental tissue and fetal tissues are
very high. Given a large intracellular
pool, a much longer duration of mater-
nal infusionwouldbe required todetect
any significant enrichment of 13C inosi-
tolm2 from
13C glucosem2.
A limitation of our study is that although the maternal
concentrations appear to be at a steady state at the time of
umbilical sampling, the in uterometabolism and turnover
for inositol and mannose are unknown, and the 2-h infu-
sion before sampling may have been inadequate for ino-
sitol. The study was limited to one fetal sample obtained
at delivery via the umbilical artery and vein cord segment.
Ideally, uterine and umbilical arteriovenous differences
could be continuouslymonitored before delivery and over
a longer time, which is a major limitation for human stud-
ies but is eminently achievable in animal studies. The fetal
turnover rates or plasma rate of appearance (Ra) for ino-
sitol andmannose are unknown. Recently, the Ra for ino-
sitol and mannose was described by Brown et al. (24) and
demonstrated a relatively high requirement for de novo
production fromglucose.Without knowledge of fetal ino-
sitolRa,wemustuse cautionwhen interpreting the results.
Our results suggest that the lack of labeled inositol in the
fetus is because inositol is not primarily maternally de-
rived; however, it is also possible that if the Ra is slow, the
duration of inositol infusion may not be sufficient to cap-
ture the origin of inositol.More information regarding the
fetalRawouldbeneeded todefinitively conclude that fetal
inositol is not maternally derived.
The finding in our study, along with other normal hu-
man and sheep pregnancy studies, of a significant trans-
placental flux of mannose into the fetal circulation sug-
gests the presence of a placental transporter (20, 21).
Future research efforts are needed to identify a specific
placental high-affinity transporter for mannose that has
been identified in other tissues (25). Whether the trans-
placental supply of mannose and fetal production of ino-
sitol remains unaltered in aberrancies of fetal growth (in-
FIG. 2. Fetomaternal MPE ratios for glucose, mannose, and inositol and 97.5% CI.
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trauterine growth restriction and macrosomia) or with
maternal diabetes remains unknown.
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